Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?

Area of Science:

• Hepatocellular carcinoma research
• Molecular targeted therapy
• Immunotherapy

Background:

• Hepatocellular carcinoma (HCC) treatment has advanced with targeted and immunotherapeutic agents.
• Tumor angiogenesis plays a critical role in HCC development and progression.
• Sorafenib, a targeted agent, is pivotal in HCC treatment after chemotherapy failures.

Purpose of the Study:

• To review the current landscape of advanced hepatocellular carcinoma treatment.
• To highlight sorafenib's role as a benchmark systemic therapy.
• To discuss future directions in HCC therapeutic strategies.

Main Methods:

• Review of existing literature on molecular targeted agents and immunotherapy in HCC.
• Analysis of sorafenib's efficacy and its position in treatment algorithms.
• Discussion of emerging strategies including underlying liver disease, mutations, and therapy integration.

Main Results:

• Sorafenib is the only systemic treatment demonstrating a statistically significant survival benefit in HCC.
• No new drug or combination therapy has surpassed sorafenib's results to date.
• Understanding underlying liver disease and tumor mutations is crucial for advancing HCC treatment.

Conclusions:

• Future HCC treatment will involve novel drug development and a focus on the progression of liver disease.
• Integrating locoregional and systemic therapies, alongside understanding mutations, is essential.
• Optimizing therapeutic strategies with existing and new agents is key for improving patient outcomes.